🇺🇸 FDA
Pipeline program

50 mg LX3305 QD

LX3305.1-106-RA

Phase 1 small_molecule completed

Quick answer

50 mg LX3305 QD for Rheumatoid Arthritis is a Phase 1 program (small_molecule) at LEXICON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
LEXICON PHARMACEUTICALS, INC.
Indication
Rheumatoid Arthritis
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials